Royalty Report: Medical, Diagnostic, Device – Collection: 322230

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Medical
  • Diagnostic
  • Device
  • Viral Infection
  • Drugs
  • Respiratory
  • Test/Monitoring
  • Disease
  • Drug Discovery
  • Vaccine
  • Bacterial Infection
  • HIV / AIDs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 322230

License Grant
Under the terms of the worldwide licensing agreement with the Licensor, the Licensee will adapt the coronavirus test to run on its T2Dx Instrument.
License Property
T2Dx Instrument has the ability to rapidly identify COVID-19.

The COVID-19 molecular diagnostic test is designed to detect the presence of the SARS-CoV-2 virus in a nasopharyngeal swab sample.

Coronavirus disease (COVID-19) is an infectious disease caused by a coronavirus (called SARS-CoV-2), a contagious respiratory illness.

Field of Use
The field of use is for the detection of the SARS-CoV-2 virus.

SARS-CoV-2 virus is a coronavirus that causes a contagious respiratory illness.

Licensee is a diagnostics company that develops innovative and proprietary technology platforms that target treatments for early detection of a variety of diseases including COVID-19 (SARS-CoV-2 virus).

IPSCIO Record ID: 306663

License Grant
The Licensee entered into a worldwide nonexclusive License Agreement with the Licensor, the primary agency of the United States government responsible for biomedical and public health research, for the use of certain patents and tangible materials to be used in the development and commercialization of a vaccine for the SARS-CoV-2 virus.
License Property
The focus is on the development of a vaccine for the SARS-CoV-2 virus and other strains of coronavirus using patented and patent-pending technology.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic.

Field of Use
Licensee focus is on developing novel antibiotics against infectious diseases; especially a vaccine for the SARS-CoV-2 virus and other strains of coronavirus using patented and patent-pending technology. The goal is accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.

IPSCIO Record ID: 380353

License Grant
Licensor granted Licensee of the Cayman Islands a worldwide exclusive license to develop, make, have made, use and have used, import, export and market certain licensed products in COVID-19 testing and diagnosis.
License Property
Licensed Products relate to a pending Chinese patent application No. CN202010232072.4 entitled “Primers for detecting novel coronavirus SAR-CoV-2, which causes COVID-19, and test kits, methods and applications thereof” and a pending U.K. patent application No. 2012480.6 entitled “Optimized primer design to stabilize the performance of RT-LAMP,” regarding the primer and molecular switch technologies that are integral to the nucleic acid amplification test.

Loop-Mediated Isothermal Amplification (the LAMP) – a patents to develop and make any reagent, product, kit, device, equipment, instrument and/or system for nucleic acid in-vitro diagnostic tests for the detection of a SARS-CoV-2. The main technical methods for COVID-19 testing include reverse transcription loop-mediated isothermal amplification (RT-LAMP), RT-PCR, serology test and antigen test. Nucleic acid amplification test, which includes RT-LAMP and RT-PCR, is the most extensively used in practice because of its high specificity, sensitivity and accuracy. The RT-LAMP technology was used to develop a viral RNA molecular test or nucleic acid amplification test for COVID-19.

Field of Use
Field of use is for the detection of a SARS-CoV-2 (COVID-19) virus.

IPSCIO Record ID: 300536

License Grant
Licensor of Hong Kong grants an exclusive, even as to Licensor, royalty-bearing and sublicenseable, including through multiple tiers, license under the Licensed Technology to, directly or through a third party, conduct research, use, Develop, offer for sale, sell, market, distribute, import, export, and otherwise Commercialize Products in the Field in the Territory, and to make, have made, conduct research, and Develop Products in the Field both inside and outside the Territory for Commercialization, sale, and distribution in the Territory.
License Property
Product means any COVID-19 diagnostic kits, including a Laboratory Developed Test produced, Developed, Commercialized, submitted for Regulatory Approval, and/or sold in any jurisdiction in the Territory, including, without limitation any of Licensor’s existing COVID-19 diagnostic kits and any future COVID-19 diagnostic kits derived from Licensor’s COVID-19 diagnostic kits. Where applicable, Product shall additionally refer to all rights and related intellectual property rights Patent rights and Know-How related to such Product.

COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Field of Use
License pertains to certain technology owned or controlled by the Licensor related to COVID-19 diagnostic kits (“Kits”).

IPSCIO Record ID: 380067

License Grant
The Japanese Licensor granted Licensee of the Cayman Islands a personal, non-transferable, non-assignable and non-exclusive licenses under certain patents, relating, in part to LAMP, to develop and make any reagent, product, kit, device, equipment, instrument and/or system for nucleic acid IVD tests for the detection of SARS-CoV-2 and to use, sell, offer for sale or otherwise dispose of the Licensor Licensed Products so made under Licensee’s own labels in the U.K. Pursuant to the Licensor Agreement, Licensee has the option to expand the license to the Licensor Licensed Patents for the Licensor Licensed Products to all countries of the world for additional one-off license fees.
License Property
Loop-Mediated Isothermal Amplification (the LAMP) – a patents to develop and make any reagent, product, kit, device, equipment, instrument and/or system for nucleic acid in-vitro diagnostic tests for the detection of a SARS-CoV-2. The main technical methods for COVID-19 testing include reverse transcription loop-mediated isothermal amplification (RT-LAMP), RT-PCR, serology test and antigen test. Nucleic acid amplification test, which includes RT-LAMP and RT-PCR, is the most extensively used in practice because of its high specificity, sensitivity and accuracy. The RT-LAMP technology was used to develop a viral RNA molecular test or nucleic acid amplification test for COVID-19.
Field of Use
Field of use is for the detection of a SARS-CoV-2 (COVID-19) virus.

IPSCIO Record ID: 348061

License Grant
Licensor, a University Foundation, desires to have the Technology developed and used to the fullest extent in the Field for the benefit of the public and is therefore willing to grant Licensee exclusive rights in the Technology.
Licensee shall, in the Field, in the Territory and during the Term, have an exclusive license to use Technology to make, manufacture, use, sell, have sold, lease, have leased, and offer for sale Licensed Products.
License Property
Technology means Inventions, Know-How, the information and data provided in NTD 110-2124, and anything claimed or described in Licensed Patent(s).

NTD 110-2124 means Foundation New Technology Disclosure 110-2124, entitled “Methods of Quantifying SARS-CoV-2 from Individual and Pooled Saliva”

Inventions – Methods of quantifying SARS-CoV-2 from individual and pooled saliva
Licensed Patents – Methods of Quantifying SARS-CoV-2 from Individual and Pooled Saliva (application pending)

Field of Use
Field means the manufacture and distribution of kits, tests, and other materials for pooled and individual COVID-19 diagnosis.

The Clarifi COVID-19 Test is a saliva-based, quantitative polymerase chain reaction (“qPCR”) test for the presence of the SARS-CoV-2 virus.

IPSCIO Record ID: 380354

License Grant
Licensor granted Licensee of the Cayman Islands a limited royalty bearing, non-exclusive, non-transferable, non-sublicensable, worldwide license under Licensor’s rights in their licensed patents to use certain Licensor products to make, have made, use, offer to sell, sell, have sold under our label and export certain licensed products relating to colorimetric LAMP for clinical diagnostic, investigational and research use.
License Property
Loop-Mediated Isothermal Amplification (the LAMP) – a patents to develop and make any reagent, product, kit, device, equipment, instrument and/or system for nucleic acid in-vitro diagnostic tests for the detection of a SARS-CoV-2. The main technical methods for COVID-19 testing include reverse transcription loop-mediated isothermal amplification (RT-LAMP), RT-PCR, serology test and antigen test. Nucleic acid amplification test, which includes RT-LAMP and RT-PCR, is the most extensively used in practice because of its high specificity, sensitivity and accuracy. The RT-LAMP technology was used to develop a viral RNA molecular test or nucleic acid amplification test for COVID-19.
Field of Use
Field of use is for the detection of a SARS-CoV-2 (COVID-19) virus.

IPSCIO Record ID: 307944

License Grant
Under the Collobaration Agreement, Licensor will make the Ii-Key Peptide vaccine technology available to the Chinese Licensees. The Chinese parties will provide facilities and personnel for the development of the COVID-19 vaccine under Licensor technical guidance. The development will include synthesis, analysis and human trials through Phase III, if warranted, in China. The Chinese parties will have exclusive rights to use and commercialize the COVID-19 technology and products in China.
License Property
The licensed property is Ii-Key Peptide vaccine technology.  Ii-Key is a technology that activates the immune response for the treatment of cancer and infectious diseases.
Field of Use
The field of use is to develop a COVID-19 vaccine.  The COVID-19 pandemic has opened significant opportunities to resurrect infectious disease vaccine platform Ii-Key Peptide vaccine technology.  COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Licensee is an affiliate of the China Technology Exchange, and is enabling the development of the COVID-19 vaccine in China.

IPSCIO Record ID: 306253

License Grant
University grants Licensee (a) an exclusive, non-transferable license, limited to the Territory and the Field, with the right to sublicense, under the Patent Rights to make, have made, use, sell, offer for sale and import Licensed Products; and (b) a non-exclusive, non-transferable license, limited to the Territory and the Field, to use the Technical Information to develop, manufacture and sell Licensed Products.
License Property
Invention PadLock-RCA-Nuclease Protection Lateral Flow Assay (PLAN-LFA) for the Detection of Pathogen Sequences at the Point of Care, known as University Technology # 2020-070 (including the RNA sequence of the same).

Licensed Product(s) means any product, process, or service (a) that is covered by the Patent Rights, infringes the Patent Rights, or would infringe the Patent Rights (but for a valid statutory exception in the U.S. or other countries); (b) the development, manufacture, use, sale or importation of which is, incorporates, uses, or is derived from, any Technical Information; or (c) meeting the qualifications of both (a) and (b).

Patent Rights US Provisional Application No. 62/989,592 “Padlock Probe-Based Rolling Circle Amplification Paired with Nuclease Protection for Point of Need Nucleic Acid Detection”

Field of Use
The field of use relating to this diagnostic device is used for the detection of Pathogen Sequences (infectious diseases) at the Point of Care.  These pathogens or biomarkers can occur in humans or animals, or contaminants in water supplies, foodstuffs, or animal feeds. In public health, sequence data are used to reconstruct the evolution of pathogens, to anticipate future spread, and to target interventions. Such sequence data are increasingly being used to track the spread of pathogens and to predict their phenotypic properties. Both applications have great potential to inform public health and treatment decisions if sequence data can be obtained and analyzed rapidly.

Pathogenic bacteria is a disease-causing bacteria. Pathogenic bacteria can contribute to many worldwide diseases, including tuberculosis, cholera, anthrax, leprosy, the bubonic plague, pneumonia, and food-borne illnesses. The most common fatal bacterial infectious diseases are respiratory infections.

The license certain intellectual property will allow Licensee to develop a device to detect virulent viral pathogens such as HIV, hepatitis C, dengue, Zika and severe acute respiratory syndrome coronavirus 2 (“SARS-Cov-2”), responsible for COVID-19.

Licensee has a technology platform that measures the signature of infectious bacteria, enabling real-time and rapid response in medical, veterinary, pharmaceutical and aquatic applications.

IPSCIO Record ID: 6962

License Grant
The Assignor hereby assigns, conveys and delivers to the Assignee, and the Assignee hereby acquires from the Assignor, all right, title and interest of the Assignor in and to the following; (i) certain inventions, formulae, manufacturing secrets, processes and know-how with respect to the manufacture of certain bio-medical products and (ii) certain intellectual property and inventions used in connection with said products.
Assignor hereby grants Assignee the right to use and display Assignor's trademarks, service marks, and trademarks and trade names that are applicable to Assignor Product(s) under this private labeling agreement. Assignee may use any of Assignor's Marks as part of its corporate, trade or other business name.
License Property
FDA 510K Cleared tests means that the following tests have been giving approval by the U.S. Food & Drug Administration to market the tests and testing device.

FDA 510K Numbers and Approved Tests
Device Name
510(K) Number

Rubella-Cube
K892051

CMV-Cube
K884842

Rotacube (Rotavirus)
K884017

Blue Dot Test for Pregnancy
K882588

First Sign (Pregnancy, HCG)
K973208

V-Trend Target IM Test (Infectious Mononucleosis)
K890041

Target Strep A
K880460

Target HCG Enzyme Immunoassay Reagents
K862247

Target ASO Test
K910073

Target HCG Test
K914303

Target HCG One-Step
K903937

V-Trend Target RF Test
K904105

Target Quantitative HCG
K890131

V-Trend Target CRP Test
K890423

Target Reader
K885254

510(K) Approved Platform Products
HCG Human chorionic gonadotropin (Pregnancy Test) Rapid enzyme immunoassay test for qualitative detection of HCG in urine, serum and plasma. HCG is a hormone produced by the developing placenta. Serum and urine levels of HCG climb rapidly, starting as soon as the week following implantation, reaching peak levels near the end of the first trimester. One-step technology offers superior speed and simplicity without sacrificing sensitive and specific results.

Strep A Detects group A streptococci, the cause of upper respiratory infections and pharyngitis. Identification is essential for the selection of appropriate antibiotic therapy to avoid complications such as acute glomerulonephritis or rheumatic fever. The test detects group A strep antigen directly from extracted throat swabs or swabs from culture plates for test confirmation.

Rubella Rapid enzyme immunoassay test for qualitative detection of rubella virus specific IgG antibody. Rubella is a highly contagious yet generally mild disease in most people. However, it has great significance in women infected with rubella, the virus may infect the placenta, multiply and induce serious damage to the fetus, including low birth weight, cardio vascular detects, mental retardation and bone defects. Therefore, all women of child bearing age, as well, as school age children and healthcare personnel should be screened for immunity to rubella.

CMV Rapid enzyme immunoassay for qualitative detection of antibody to Cytomegalovirus in serum and plasma. Cytomegalovirus (CMV) is human viral pathogen belonging to the herpes family. Infection in humans is wide spread and usually results in asymptomatic disease. However, severe symptomatic infections pose a very significant risk in infants and immunocomprised patients.

Rotavirus Rapid enzyme immunoassay test for qualitative detection of human rotavirus particles and antigens in human fecal specimens. Rotavirus is a major cause of gastroenteritis in infants, young children and the elderly. During the winter months a portion of gastroenterics in children is due to rotavirus infection. The disease manifests with the symptoms of vomiting diarrhea, and fever. Rapid and accurate diagnosis is important to avoid inappropriate antibiotic therapy, provide proper treatment early and to prevent spread of nosocmial infection.

Mono Qualitative and quantitative detection of heterophile antibodies associated with infectious mononucleosis. IM is an acute disease caused by the Epstein Barr virus. Heterophile antibodies are the primary antibodies, which appear in the patient’s serum, usually 1 to3 weeks after the onset of symptoms Common symptoms include fatigue, pharyngitis, fever, lymphadenopatherapy and splenomegaly.

CRP C-reactive protein is an acute phase protection. The test is a solid phase gold immunoassay for the detection of CRP. Quantitative CRP measurements have been found to provide reliable early indication of postoperative inflammatory complications if monitored on a daily basis. CRP is also predictive of clinical cardiovascular disease.

Reader The Target System Reader is designed to interpret selected membrane enzyme immunoassays. The instrument is designed for laboratory, emergency room or field use and requires only a few minutes to learn to operate. The reader permits more precise, accurate readings of test results than visual interpretation.

Field of Use
Field of Use means diagnostic testing for any disease or medical condition that can be transmitted by one human to another within the diagnostic health care industry, mobile and non-mobile, which industry focuses on providing healthcare and diagnostic solutions and services, but not limited to Hospitals, Emergency Medical Vehicle Care, Mobile Health Clinics, Schools, Government Agencies, retail drug stores, corporations, Hospices, Assisted Living and Nursing Homes, Home Health Care, and Physician’s offices. The Field of Use herewith does not include diagnostic or analytical testing within the Veterinary and Livestock, Environmental Testing or any military, law enforcement, bioterrorism or homeland security related industries.

IPSCIO Record ID: 266

License Grant
The Assignor hereby assigns, conveys and delivers to the Assignee, and the Assignee hereby acquires from the Assignor, all right, title and interest of the Assignor in and to the following; (i) certain inventions, formulae, manufacturing secrets, processes and know-how with respect to the manufacture of certain bio-medical products and (ii) certain intellectual property and inventions used in connection with said products.
License Property
FDA 510K Cleared tests means that the following tests have been giving approval by the U.S. Food & Drug Administration to market the tests and testing device.

FDA 510K Numbers & Approved Tests

Device Name

                                           510(K) Number

Rubella-Cube

                                                K892051

CMV-Cube

                                                K884842

Rotacube (Rotavirus)

                                K884017

Blue Dot Test for Pregnancy
                                
K882588

First Sign (Pregnancy, HCG)

                                K973208

V-Trend Target IM Test (Infectious Mononucleosis)
K890041

Target Strep A

                                                K880460

Target HCG Enzyme Immunoassay Reagents

K862247

Target ASO Test

                                                K910073

Target HCG Test

                                                K914303

Target HCG One-Step
                                  
K903937

V-Trend Target RF Test
                                
K904105

Target Quantitative HCG
                                  
K890131

V-Trend Target CRP Test
                                        
K890423

Target Reader

                                                K885254

510(K) Approved Platform Products
HCG Human chorionic gonadotropin (Pregnancy Test) Rapid enzyme immunoassay test for qualitative detection of HCG in urine, serum and plasma. HCG is a hormone produced by the developing placenta. Serum and urine levels of HCG climb rapidly, starting as soon as the week following implantation, reaching peak levels near the end of the first trimester. One-step technology offers superior speed and simplicity without sacrificing sensitive and specific results.

Strep A Detects group A streptococci, the cause of upper respiratory infections and pharyngitis. Identification is essential for the selection of appropriate antibiotic therapy to avoid complications such as acute glomerulonephritis or rheumatic fever. The test detects group A strep antigen directly from extracted throat swabs or swabs from culture plates for test confirmation.

Rubella Rapid enzyme immunoassay test for qualitative detection of rubella virus specific IgG antibody. Rubella is a highly contagious yet generally mild disease in most people. However, it has great significance in women infected with rubella, the virus may infect the placenta, multiply and induce serious damage to the fetus, including low birth weight, cardio vascular detects, mental retardation and bone defects. Therefore, all women of child bearing age, as well, as school age children and healthcare personnel should be screened for immunity to rubella.

CMV Rapid enzyme immunoassay for qualitative detection of antibody to Cytomegalovirus in serum and plasma. Cytomegalovirus (CMV) is human viral pathogen belonging to the herpes family. Infection in humans is wide spread and usually results in asymptomatic disease. However, severe symptomatic infections a very significant risk in infants and immunocomprised patients.

Rotavirus Rapid enzyme immunoassay test for qualitative detection of human rotavirus particles and antigens in human fecal specimens. Rotavirus is a major cause of gastroenteritis in infants, young children and the elderly. During the winter months a portion of gastroenterics in children is due to rotavirus infection. The disease manifests with the symptoms of vomiting diarrhea, and fever. Rapid and accurate diagnosis is important to avoid inappropriate antibiotic therapy, provide proper treatment early and to prevent spread of nosocmial infection.

Mono Qualitative and quantitative detection of heterophile antibodies associated with infectious mononucleosis. IM is an acute disease caused by the Epstein Barr virus. Heterophile antibodies are the primary antibodies, which appear in the patient’s serum, usually 1 to3 weeks after the onset of symptoms Common symptoms include fatigue, pharyngitis, fever, lymphadenopatherapy and splenomegaly.

CRP C-reactive protein is an acute phase protection. The test is a solid phase gold immunoassay for the detection of CRP. Quantitative CRP measurements have been found to provide reliable early indication of postoperative inflammatory complications if monitored on a daily basis. CRP is also predictive of clinical cardiovascular disease.

Reader The Target System Reader is designed to interpret selected membrane enzyme immunoassays. The instrument is designed for laboratory, emergency room or field use and requires only a few minutes to learn to operate. The reader permits more precise, accurate readings of test results than visual interpretation.

Field of Use
Field of Use is defined as Diagnostic testing for any disease or medical condition that can be transmitted by one human to another within the diagnostic health care industry, mobile and non-mobile. The Field of Use herewith does not include diagnostic or analytical testing within the Veterinary and Livestock, Environmental Testing or any military, law enforcement, bioterrorism or homeland security related industries.
Such testing to be done at the point of care, such point of care may include but are not limited to places such as

·
Hospitals

·
Emergency Medical Vehicle Care

·
Mobile Health Clinics

·
Schools

·
Government Agencies

·
Retail Drug Stores

·
Corporations

·
Hospices

·
Assisted Living and Nursing Homes

·
Home Health Care

·
Physician’s offices

IPSCIO Record ID: 315783

License Grant
The Israelis Company received an exclusive global license to purchase Israelis Licensor products for the purpose of reselling the products, focusing on a unique Biogel for the protection from COVID-19 virus.
License Property
BioGel products are a blend of all natural organic herbs and minerals without the potential side-effects of any antibiotics or steroids to mitigate biological threats such as SARS-CoV-2, COVID-19, bacteria and more.

Company developed an innovative Capture & Contain technology, designed to safely prevent allergens and virus intrusion through the upper airways and eye cavities. Company’s technology is comprised of a Biogel that is applied topically, is preventative, safe, easy to use and can be formulated both for wet and dry administration.

Company’s goal is to provide protection from the spread and contamination of Coronavirus inhaled or absorbed through the upper airways and eyes. The final product shall take the form of a spray or eyedrops, made of mucoadhesive biological gel (a gel that contains covalently bound specific Abs against SARS-CoV-2 specific surface proteins) aiming to lower the intrusion levels of the virus through the nasal and buccal cavities for several hours.

Field of Use
The rights granted are for the purpose of reselling the products worldwide. The products are developed to provide protection from the spread and contamination of Coronavirus inhaled through the upper airways and eyes, using spray or eyedrops made of mucoadhesive biological gel (a gel that contains covalently bound specific Abs against SARS-CoV-2 specific surface proteins),  aiming to lower the intrusion levels of the virus through the nasal and buccal cavities for several hours. Similarly, the products may provide protection from airborne allergens through the upper airways and eyes, reducing the allergic reaction due to a lower amount of allergens reaching its target cells.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.